{"id":"NCT01531959","sponsor":"Massachusetts General Hospital","briefTitle":"Midodrine for the Treatment of Refractory Hypotension","officialTitle":"Midodrine for the Treatment of Refractory Hypotension in Patients Otherwise Ready for Discharge From the ICU","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-04","primaryCompletion":"2019-06","completion":"2019-06","firstPosted":"2012-02-13","resultsPosted":"2019-09-06","lastUpdate":"2020-10-28"},"enrollment":139,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypotension","Critical Illness"],"interventions":[{"type":"DRUG","name":"Midodrine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Midodrine","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"We hypothesize that midodrine treatment of refractory hypotension in patients otherwise ready for discharge from the ICU shortens duration of receiving IV vasopressors and SICU length of stay without increasing MGH length of stay or putting the patient at risk of being readmitted to an ICU.","primaryOutcome":{"measure":"Time Until Discontinuation of IV Vasopressors","timeFrame":"From initiation of the study drug until discontinuation of IV vasopressors, assessed up to 400 hours","effectByArm":[{"arm":"Midodrine","deltaMin":23.5,"sd":null},{"arm":"Placebo","deltaMin":22.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":12},"locations":{"siteCount":3,"countries":["United States","Australia"]},"refs":{"pmids":["28327122"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":66},"commonTop":["Hypertension","Bradycardia","Atrial fibrillation","Nausea","Lab parameter change"]}}